Laser Immunotherapy With and Without Topical Anti-PD1 in Basal Cell Carcinomas

NCT04570683 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

BCC - Basal Cell Carcinoma
Immune Response
Immunotherapy
Ablative Fractionated Laser

Interventions

DRUG: Nivolumab 10 MG/ML
DEVICE: Ablative fractionated laser

Sponsor

Bispebjerg Hospital